43 reports of this reaction
1.3% of all ALFUZOSIN HYDROCHLORIDE reports
#19 most reported adverse reaction
HYPONATRAEMIA is the #19 most commonly reported adverse reaction for ALFUZOSIN HYDROCHLORIDE, manufactured by Cipla USA Inc.. There are 43 FDA adverse event reports linking ALFUZOSIN HYDROCHLORIDE to HYPONATRAEMIA. This represents approximately 1.3% of all 3,364 adverse event reports for this drug.
Patients taking ALFUZOSIN HYDROCHLORIDE who experience hyponatraemia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HYPONATRAEMIA is a less commonly reported adverse event for ALFUZOSIN HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to hyponatraemia, the following adverse reactions have been reported for ALFUZOSIN HYDROCHLORIDE:
The following drugs have also been linked to hyponatraemia in FDA adverse event reports:
HYPONATRAEMIA has been reported as an adverse event in 43 FDA reports for ALFUZOSIN HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
HYPONATRAEMIA accounts for approximately 1.3% of all adverse event reports for ALFUZOSIN HYDROCHLORIDE, making it a notable side effect.
If you experience hyponatraemia while taking ALFUZOSIN HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.